“Clinical research is critical for advancing new therapies and care for cancer patients and we are enthusiastic about broadening our clinical trial offering with the inclusion of VIPER”
“Clinical research is critical for advancing new therapies and care for cancer patients and we are enthusiastic about broadening our clinical trial offering with the inclusion of VIPER,” said Christian Thomas, M.D., director of clinical research at NECS. “We look forward to testing the speed, efficacy and reporting capabilities of VIPER in our research department. We are committed to ensuring that every patient we see has the opportunity to access the newest therapies in development and receive the best possible care for their specific diagnosis. The integration of VIPER will allow us to expand opportunities for patients and free up research resources.”
It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. Limited site capacity and resources play a role in the challenge to recruit and enroll, as well as low patient engagement. All of these challenges have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients -- at the time of diagnosis -- to appropriate trials through the ingestion and analysis of customized genomic data, electronic medical records and pathology data.
“The clinical trial program at NECS is already extremely comprehensive -- the team prioritizes emerging research and takes a proactive role in patient education and engagement,” said Greg Andreola, chief revenue officer at Deep Lens. “However, with the increasing number of precision medicine trials that include very complex and narrow eligibility criteria, study sites often find it challenging and labor intensive to manage the recruitment process themselves. We’re excited to help NECS include VIPER and other Deep Lens services to recruit more eligible patients to their trials portfolio.”
Deep Lens’ VIPER will be integrating directly to the NECS EMR (Flatiron Health’s OncoEMR), molecular data feeds (Caris Life Sciences and Tempus) and pathology feeds to automatically identify qualified patients for clinical trials. Like NECS, any practice that utilizes OncoEMR can easily integrate VIPER and all other Deep Lens screening services free of charge.
About New England Cancer Specialists (NECS)
NECS is an independent medical oncology and hematology practice dedicated to the highest quality team-based care for every patient. Comprised of 13 physicians who are nationally recognized for their expertise and experience, they participate in more clinical trials than any other practice in Maine. With partnerships across the state and around the region, NECS aims to further increase the availability of and access to novel cancer therapeutics and programmatic advancements. For more than 30 years, NECS has maintained a relationship with the Dana-Farber Cancer Institute in Boston and is a Member of the Dana-Farber Cancer Care Collaborative. For more information, visit www.newenglandcancerspecialists.org/.
About Deep Lens
Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows that combine lab, EMR, and genomic data to match cancer patients to clinical trials and precision therapies at the time of diagnosis, accelerating recruitment and compressing study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.